Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Long-Term Debt Repayments (2017 - 2025)

Adma Biologics' Long-Term Debt Repayments history spans 7 years, with the latest figure at -$31.6 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to -$31.6 million; the TTM value through Dec 2025 reached -$29.1 million, changed N/A, while the annual FY2025 figure was $938000.0, N/A changed from the prior year.
  • Long-Term Debt Repayments reached -$31.6 million in Q4 2025 per ADMA's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $100.0 million in Q1 2022 to a low of -$31.6 million in Q4 2025.